title: [Gene therapy for osteoarticular disorders].
abstract: Osteoarticular disorders are the major cause of disability in Europe and North America. It is estimated that rheumatoid arthritis affects 1 % of the population and that more than two third of people over age 55 develop osteoarthritis. Because there are no satisfactory treatments, gene therapy offers a new therapeutic approach. The delivery of cDNA encoding anti-arthritic proteins to articular cells has shown therapeutic efficacy in numerous animal models in vivo. Through the development and the experimental progresses that have been made for both rheumatoid arthritis and osteoarthritis, this review discusses the different gene therapy strategies available today and the safety issues with which they may be associated. Among the different vectors available today, adeno-associated virus seems the best candidate for a direct in vivo gene delivery approach for the treatment of joint disorders.
authors.affiliation: Department of Orthopaedics and Rehabilitation, Gene therapy laboratory, University of Florida, 1600 SW Archer Rd, Rm M2-210, Gainesville, FL 32610, USA. gouzej@ortho.ufl.edu
authors.forename: Jean-Noël
authors.initials: JN
authors.lastname: Gouze
authors.forename: Christopher H
authors.initials: CH
authors.lastname: Evans
authors.forename: Steven C
authors.initials: SC
authors.lastname: Ghivizzani
authors.forename: Elvire
authors.initials: E
authors.lastname: Gouze
mesh_terms: D000368:Aged; D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D002358:Cartilage, Articular / Q000378:metabolism / Q000473:pathology; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000235:genetics; D018076:DNA, Complementary / Q000008:administration & dosage / Q000627:therapeutic use; D000229:Dependovirus / Q000235:genetics; D004285:Dogs; D004318:Doxycycline / Q000494:pharmacology; D000068800:Etanercept; D015870:Gene Expression / Q000187:drug effects; D005813:Genes, Synthetic; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods; D005822:Genetic Vectors / Q000009:adverse effects / Q000627:therapeutic use; D000882:Haplorhini; D006736:Horses; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007270:Injections, Intra-Articular; D051379:Mice; D008875:Middle Aged; D010003:Osteoarthritis / Q000503:physiopathology / Q000628:therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000235:genetics; D020123:Sirolimus / Q000494:pharmacology
chemical_list: D016207:Cytokines; D018076:DNA, Complementary; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II; D004318:Doxycycline; D000068800:Etanercept; D020123:Sirolimus